A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Summary
The purpose of this study is to determine whether PF-03654746 is effective in the treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD). This will be a randomized, double-blind, crossover study in which adults with ADHD will receive 3 weeks of treatment with PF-03654746, either a low dose (1 mg), or flexible dose (0.50 mg titrated up to 2 mg), and 3 weeks of placebo. A washout period will separate the 2 treatment periods. Participants will be required to washout of prior ADHD medication before entering the study. Participants will be required to come to the site for 10 visits over approximately a 10-week period.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-09
- Completion
- 2008-09
Outcome
Missed primary endpoint
registry PF-03654746 (Low Dose) vs Placebo; p = 0.6749; Least Squares (LS) Mean Difference 0.7947 NCT00531752 ↗
registry PF-03654746 (Flexible Dose) vs Placebo; p = 0.4886; LS Mean Difference 1.4176 NCT00531752 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-03654746 | Small molecule | 1 mg | — |
| Subject | PF-03654746 | Small molecule | 2 mg | — |